NXGL

NEXGEL, Inc.
CAPPED RATING

NEXGEL, Inc. (NXGL) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Revisions (F). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
B-
Factor Score 3.0 / 5.0
Growth
B+
Factor Score 3.6 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
D-
Factor Score 0.8 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.9
EV / EBITDA -2.2
Rev Growth YoY 27.8%
Gross Margin 35.1%
Price Return 3M -66.5%
Price Return 12M -91.7%
Catalyst Signal 0.00
Market Cap $1.8M
TTM Revenue $12.1M
Price / Sales 0.2
ROE -115.1%

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) B+ (3.6) C+ (2.8) D- (0.8) F (0.0) C- (2.0)
2026-11-06 B- (3.0) B+ (3.6) C+ (2.8) D- (1.0) F (0.0) C- (2.1)
2026-10-30 B- (3.0) B+ (3.6) B- (2.9) D- (0.7) F (0.0) C- (2.0)
2026-10-23 B- (3.0) B+ (3.6) C+ (2.8) D- (0.9) F (0.0) C- (2.1)
2026-10-16 B- (3.0) B+ (3.6) C+ (2.8) D- (0.9) F (0.0) C- (2.1)
Page 1 of 4